BOLT BIOTHERAPEUTICS INC's ticker is BOLT and the CUSIP is 097702104. A total of 41 filers reported holding BOLT BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $207,554 | +28528.1% | 276,739 | -46.5% | 0.00% | -100.0% |
| Q1 2024 | $725 | +45.3% | 517,637 | +16.3% | 0.00% | 0.0% |
| Q4 2023 | $499 | +52.6% | 445,273 | +41.7% | 0.00% | 0.0% |
| Q3 2023 | $327 | -47.2% | 314,189 | -35.1% | 0.00% | 0.0% |
| Q2 2023 | $619 | -2.5% | 483,939 | +6.0% | 0.00% | 0.0% |
| Q1 2023 | $635 | +10.6% | 456,739 | +3.4% | 0.00% | 0.0% |
| Q4 2022 | $574 | -99.9% | 441,539 | +12.1% | 0.00% | 0.0% |
| Q3 2022 | $583,000 | -47.0% | 393,858 | -26.9% | 0.00% | 0.0% |
| Q2 2022 | $1,099,000 | +38.2% | 538,573 | +85.7% | 0.00% | 0.0% |
| Q1 2022 | $795,000 | +82.3% | 290,100 | +226.3% | 0.00% | 0.0% |
| Q4 2021 | $436,000 | -56.5% | 88,900 | +12.1% | 0.00% | 0.0% |
| Q3 2021 | $1,003,000 | +7.3% | 79,300 | +31.1% | 0.00% | 0.0% |
| Q2 2021 | $935,000 | – | 60,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $29,242,000 | 11.52% |
| Nan Fung Group Holdings Ltd | 1,166,952 | $18,041,000 | 5.60% |
| Novo Holdings A/S | 4,503,991 | $69,632,000 | 3.09% |
| Vivo Capital, LLC | 3,871,291 | $59,850,000 | 2.59% |
| Sofinnova Investments, Inc. | 2,754,437 | $42,584,000 | 2.45% |
| Ally Bridge Group (NY) LLC | 412,267 | $6,374,000 | 1.58% |
| Samsara BioCapital, LLC | 737,459 | $11,401,000 | 1.41% |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $11,125,000 | 1.04% |
| RA Capital Management | 2,378,325 | $36,769,000 | 0.59% |
| Rock Springs Capital Management LP | 1,619,248 | $25,034,000 | 0.50% |